相关实验视频

Updated: May 24, 2025

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

瑞醇衍生物修饰的Ru (II) 复合物:合成,表征,体外和体外抗癌研究

Wuyang Hua¹, Fenglin Li¹, Ping Yang¹

¹School of Food Science and Nutrition Engineering, Jilin Agricultural Science and Technology University, 77(th) Han Lin Road, Jilin City 132101, China; Jilin Province Brewing Technology Science and Technology Innovation Center, 77(th) Han Lin Road, Jilin City 132101, China.

Journal of inorganic biochemistry

|March 6, 2025

概括

这项研究介绍了一种新型的 (Ru4) 复合物与复星衍生物配体,显示出强大的光激活抗癌活性. Ru4有效地抑制癌细胞迁移,入侵和干细胞,在体内毒性最小.

科学领域:

协调化学协调化学
光动力学疗法光动力学疗法
癌症研究癌症研究

背景情况:

(II) 复合物是癌症治疗的有希望的光敏化剂.
连接体设计对于调整光物理和生物特性至关重要.
复星衍生物具有增强生物活性的潜力.

研究的目的:

设计和合成新型的Ru(II) 复合物,其中包括作为连接体的白醇衍生物 (氨基-Res).
评估这些复合物的光动力学抗癌疗效.
调查化合物的作用机制和体内疗效.

主要方法:

合成和表征Ru(II) 复合物与氨基-Res联体.
光物理性质的评估.
在体外评估抗癌活性,细胞吸收和作用机制 (迁移,入侵,茎状).
在体内瘤生长抑制研究.

主要成果:

一个代表性的复合体Ru4表现出强大的520nm光激活抗癌活性.
与对照复合物相比,Ru4显示出更高的脂友性 (LogP_O/W) 和细胞积累.
机制研究显示Ru4抑制癌细胞迁移,入侵和干细胞.
在体内研究表明显著的瘤生长抑制没有明显的系统性毒性.

结论:

设计的Ru(II) 复合体 (Ru4) 与氨基-Res联体是用于癌症治疗的强有力的光敏感剂.
抗癌生物功能主要来自氨基-Res联体.
Ru4显示出进一步发展的希望,作为一种光激活的抗癌剂,具有良好的体内疗效和安全性.

关键词:

癌细胞的入侵癌细胞的入侵癌症细胞干细胞性癌症细胞干细胞性在体内研究研究体内研究.光动力学疗法是一种光动力学疗法.这是一种resveratrol衍生物.鲁 (II) 复合体是一个复合体.

更多相关视频

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

Published on: March 18, 2015

相关概念视频

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Phase II Reactions: Miscellaneous Conjugation Reactions

Phase II Reactions: Miscellaneous Conjugation Reactions

Phase II biotransformations are detoxification mechanisms that conjugate xenobiotics with endogenous substances, neutralizing their toxicity.
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...